After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. After-hours trades for NRX Pharmaceuticals Inc (NRXP) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.0158, or 5.02%, to $0.3307. The NRX Pharmaceuticals Inc has recorded 1,536 volume in the after hours trading session. Earlier, Yahoo Finance discussed this stock as it revealed NRx Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 14, 2023.
NRXP belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $0.31 and fluctuated between $0.3900 as its day high and $0.2801 as its day low. The current market capitalization of NRX Pharmaceuticals Inc is $26.21M. A total of 0.64 million shares were traded on the day, compared to an average of 1.42M shares.
Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, NRXP has seen 4 BUY and 0 SELL insider trades, representing the acquisition of 405,000 and the disposition of 0 shares. Over the last 12 months, there were 21 BUYs and 7 SELLs from insiders. Insiders purchased 1,069,832 shares during that period but sold 938,108.
In the most recent transaction, Hurvitz Chaim bought 70,000 shares of NRXP for 0.29 per share on Aug 30. After the transaction, the Director now owns 570,000 company shares. In a previous transaction on Aug 30, Gorovitz Aaron bought 35,000 shares at 0.32 per share. NRXP shares that Director owns now total 105,000.
Among the insiders who bought shares, Javitt Jonathan C acquired of 100,000 shares on Aug 23 at a per-share price of $0.33. This resulted in the Chief Scientist holding 446,332 shares of NRXP after the transaction. In another insider transaction, Javitt Jonathan C bought 200,000 shares at $0.32 per share on Aug 22. Company shares held by the Chief Scientist now total 346,332.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for NRXP in the last 3 months, the mean price target is $3.08 with high estimates of $5.25 and low estimates of $2.00. In terms of 52-week highs and lows, NRXP has a high of $1.54 and a low of $0.22.
As of this writing, NRXP has an earnings estimate of -$0.12 per share for the current quarter. EPS was calculated based on a consensus of 1 estimates, with a high estimate of -$0.12 per share and a lower estimate of -$0.12. The company reported an EPS of -$0.16 in the last quarter, which was -14.30% lower than expectations of -$0.14.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. NRXP’s latest balance sheet shows that the firm has $27.61M in Cash & Short Term Investments as of fiscal 2021. There were $518.00k in debt and $11.92M in liabilities at the time. Its Book Value Per Share was -$0.03, while its Total Shareholder’s Equity was $20.81M.
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for NRXP is Buy with a score of 4.67.